Jazz Pharmaceuticals JAZZ Fair Value Measurement Disclosure

Fair Value Measurement Disclosure at other companies

AmgenAMGN

——

BiogenBIIB

——

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinancialLiabilitiesFairValueDisclosure.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Jazz Pharmaceuticals's fair value measurement disclosure?: Jazz Pharmaceuticals (JAZZ) reported fair value measurement disclosure of $8.5M in Q1 2026.